scientific research
  • The company has domestic leading core technology platforms such as plasmid DNA production, lentivirus vector production, car-t molecular design...
  • Among T cell subsets, CD8 + population is the main force to kill tumor cells. Therefore, increasing the proportion of CD8 + Car + subsets...
  • The company has a GMP workshop for cell therapy, molecular biology and cell biology laboratories in line with international standards, as well...
  • The company has domestic leading plasmid DNA production, lentivirus vector production and car-t molecular design / verification / production...
Our commitment to technology
With the goal of developing immunotherapy products and targeted drugs to solve cancer patients, we will jointly make a contribution to cancer research, new biological drug research and development and immunotherapy drug development in China
Learn more
About us

Suzhou Fangde Menda new drug development Co., Ltd. was founded by a team of senior returnees and registered in Wujiang Development Zone in July 2012, with a registered capital of 10 million yuan. In 2019, the company obtained a round of PREA financing of 65 million yuan led by a well-known industrial fund. The company focuses on the development and clinical application of tumor immune cell therapy drugs dominated by allogeneic chimeric antigen receptor T cell (thiscart) platform technology and targeted at first in class. & nbsp; & nbsp; & nbsp; The company has established a GMP workshop for cell therapy, molecular biology and cell biology laboratories in line with international standards, as well as an advanced quality control laboratory, and is carrying out clinical research on allogeneic cart cell drugs for targets such as CD19, CD22 and BCMA.

The company adheres to the guidance of clinical demand, talents as the foundation, technology as the support, capital as the link, the purpose of benefiting human health, the goal of pursuing the development of immunotherapy products and targeted drugs to solve cancer patients, and relying on strong R & D strength, the company will jointly make a contribution to cancer research, new biological drug research and development and immunotherapy drug development in China.

NEWS CENTER

Enterprise display

Learn more
Contact us
Address

Floor 4, No. 7, Wujiang science and Technology Pioneer Park, 2358 Chang'an Road, Wujiang District, Suzhou

Fax

0512-63936618

Website

www.fundamentatx.com

Zip code

215200

X

Wechat QR code

微信号:

(Click micro signal copy)

  Open wechat 

Wechat has been copied. Please open wechat to add details!